Skip to main content

Table 1 Demographics of the two sample sets in this study

From: Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease

 

CT

AD

P-value

ROW discovery set

 N

18

27

-

 AAD, yr

76.3 ± 7.1

84.5 ± 8.0

0.001a

 Gender, % (F : M)

27.8 : 72.2

63.0 : 37.0

0.033b

 PMI, hr

9.6 ± 9.4

13.4 ± 11.6

0.158a

 BW, g

1268 ± 127

1156 ± 120

0.003a

 RIN

  TC

7.9 ± 0.8

7.1 ± 1.2

0.006a

 Hemolysis ratio

  Serum

1.9 ± 0.6

1.7 ± 0.5

0.105a

  APOE

  Genotype, % (ε3*3 : ε3*4 : ε4*4)

55.6 : 44.4 : 0.0

44.4 : 25.9 : 29.6

0.550c

  Allele, % (ε3 : ε4)

77.8 : 22.2

57.4 : 42.6

0.069c

NIG validation set

 N

22

36

-

 AAE, yr

73.7 ± 8.4

74.7 ± 7.3

0.556a

 Gender, % (F : M)

80.0 : 20.0

63.9 : 36.1

0.333b

 MMSE

29.3 ± 0.7

19.3 ± 5.4

4.8.E-08a

 Hemolysis ratio

  Serum

1.3 ± 0.2

1.3 ± 0.2

0.316a

  APOE

  Genotype, % (ε3*3 : ε3*4)

85.7 : 14.3

55.6 : 44.4

0.056c

  Allele, % (ε3 : ε4)

92.9 : 7.1

77.8 : 22.2

0.090c

  1. Abbreviations: AAD age at death, AAE age at examination, AD Alzheimer’s disease, APOE apolipoprotein E, BW brain weight, CT control, F female, g grams, hr hours, M male, MMSE mini-mental state examination, PMI postmortem interval, RIN RNA integrity number, TC temporal cortex, yr years
  2. aCalculated by Mann-Whitney U-test between AD and CT
  3. bCalculated by Fisher’s exact test for gender distribution
  4. cCalculated by Fisher’s exact test for APOE ε4 allele carrier status (ε4 carrier and ε4 non-carrier)
  5. Data are presented as the mean ± standard deviation
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us